Leukemia stem cell test for AML relapse in children
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML).
- You must be 18 years old or younger.
- You must be able to understand and sign a consent form.
- You should not have severe heart, liver, or kidney problems.
- You should not have a severe infection.
- You should not have other health issues that would prevent chemotherapy or a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test that measures tumor DNA (called ctDNA) can track how well treatment is working in children with acute leukemia. The goal is to see if the blood test can give the same information as a bone marrow test, which is more invasive.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
This study tests a new lab method to screen for acute myeloid leukemia (AML), including a rare subtype called acute promyelocytic leukemia. It may help doctors diagnose and classify AML more quickly and accurately.
This study uses blood samples from people with acute myeloid leukemia (AML) and from healthy stem cell donors to learn how to make immune cells better at killing cancer. The goal is to develop a new type of treatment that helps the body's own defenses fight the disease.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.